Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing first- and best-in-class cellular immunotherapies for hematological cancers and solid tumors, as well as orphan inherited blood diseases.Our product candidates are differentiated by the inclusion of powerful molecular switches designed to eliminate, reduce or activate therapeutic cells, and thereby potentially provide greater efficacy and safety compared to the current generation of cell therapies. Our approach has yielded highly encouraging results to date from our lead BPX-501 program in the haploidentical transplant setting, as children with hematological cancers and life-long genetic blood diseases were able to leave the hospital in remission or disease-free, respectively. We believe this reflects the promise of our cellular control therapies to transform standard of care—and the lives of patients and their families. We have orphan drug designation from the U.S. FDA and the EMA for both BPX-501 for treatment in HSCT, and for activator agent rimiducid for the treatment of GvHD.

Bank Name Bellicum Pharmaceuticals, Inc.
Stock Exchange NASDAQ
Symbol BLCM
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman
CEO Mr. Richard A. Fair
Employees 137
Website www.bellicum.com
Registered Year 2004

UpdateContent
UpdateContent
UpdateContent